10x Genomics Intrinsic Stock Value – Cwm LLC Unloads 2302 Shares of 10x Genomics, Inc
December 31, 2023
☀️Trending News
Recently, Cwm LLC has unloaded 2302 shares of 10x Genomics ($NASDAQ:TXG), Inc., a leading biotechnology company that specializes in building products to interrogate, understand, and master biology. 10x Genomics is known for its gene sequencing technology, which helps researchers and clinicians to explore the vast complexities of the human genome. In addition to their sequencing technology, they also offer a comprehensive suite of products and solutions with applications in cancer biology, immunology, single-cell genomics, and more. 10x Genomics has seen great success as a publicly-traded company.
This recent sale of 2302 shares by Cwm LLC is an indication of the bullish sentiment surrounding the company. With its innovative products and solutions in genomics, 10x Genomics looks poised to continue its growth and success as a business.
Market Price
On Tuesday, 10X GENOMICS, Inc. saw a slight dip in its stock price, as Cwm LLC unloaded 2302 shares of the company. 10X GENOMICS opened at $57.1 and closed at $56.5, representing a drop of 0.1% from the previous closing price of 56.6. This move by Cwm LLC caused a slight decrease in the stock price, though the impact was minimal. It remains to be seen if this move will have any long-term effects on the stock price of 10X GENOMICS. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 10x Genomics. More…
| Total Revenues | Net Income | Net Margin |
| 590.98 | -223.36 | -37.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 10x Genomics. More…
| Operations | Investing | Financing |
| -27.23 | 87.22 | 13.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 10x Genomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 948.54 | 203.32 | 6.3 |
Key Ratios Snapshot
Some of the financial key ratios for 10x Genomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 31.2% | – | -37.0% |
| FCF Margin | ROE | ROA |
| -19.1% | -17.7% | -14.4% |
Analysis – 10x Genomics Intrinsic Stock Value
At GoodWhale, we have conducted an analysis of 10X GENOMICS‘s wellbeing. Our proprietary Valuation Line has calculated that the intrinsic value of 10X GENOMICS’ share is around $111.1. Currently, 10X GENOMICS’ stock is traded at $56.5, which is significantly undervalued by 49.2%. This presents a unique opportunity for investors to buy the stock below its intrinsic value. As a result, we recommend investing in 10X GENOMICS as it presents an attractive investment opportunity. More…
Peers
The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.
– Certara Inc ($NASDAQ:CERT)
Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.
– Omnicell Inc ($NASDAQ:OMCL)
Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.
Summary
10x Genomics, Inc. recently saw an investment activity by Cwm LLC, who sold 2302 shares of the company’s stock. This follows an overall positive trend of the company’s stock, which has seen a steady appreciation in value over the past few months. Analysts attribute this to 10x Genomics, Inc.’s innovative technology and growth in the genomics sector.
The company has seen strong sales growth, led by its products for single cell genomics and gene expression. 10x Genomics, Inc. also has strong liquidly and a solid balance sheet, making it an attractive investment opportunity for those looking to capitalize on the potential of the genomics sector.
